Moderna, Inc. (NASDAQ:MRNA) Receives Consensus Rating of “Reduce” from Analysts

Shares of Moderna, Inc. (NASDAQ:MRNA) have been given a consensus recommendation of “Reduce” by the eighteen ratings firms that are covering the firm, MarketBeat.com reports. Five investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $28.7692.

Several research firms have recently issued reports on MRNA. Leerink Partners reissued an “underperform” rating on shares of Moderna in a report on Friday, January 30th. UBS Group downgraded shares of Moderna from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $40.00 to $34.00 in a research note on Tuesday, January 6th. Wolfe Research reissued an “underperform” rating and issued a $17.00 target price on shares of Moderna in a report on Thursday, November 20th. Citigroup reaffirmed a “neutral” rating on shares of Moderna in a report on Monday, January 19th. Finally, Morgan Stanley decreased their price objective on shares of Moderna from $30.00 to $28.00 and set an “equal weight” rating on the stock in a research note on Friday, December 12th.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 23,853 shares of the company’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the completion of the sale, the director directly owned 3,924 shares in the company, valued at $115,679.52. This represents a 85.87% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 10.90% of the company’s stock.

Institutional Investors Weigh In On Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. Rothschild Investment LLC grew its stake in shares of Moderna by 94.1% during the second quarter. Rothschild Investment LLC now owns 920 shares of the company’s stock worth $25,000 after buying an additional 446 shares during the last quarter. Atlantic Union Bankshares Corp bought a new position in shares of Moderna in the 2nd quarter valued at $26,000. Whittier Trust Co. acquired a new stake in shares of Moderna during the 2nd quarter valued at $28,000. MUFG Securities EMEA plc bought a new stake in Moderna during the 2nd quarter worth $28,000. Finally, Flagship Harbor Advisors LLC bought a new position in Moderna in the fourth quarter valued at about $31,000. 75.33% of the stock is owned by institutional investors.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Signed a five-year strategic agreement with the Mexican government to supply respiratory vaccines and transfer mRNA manufacturing technology to local partner Liomont — strengthens revenue visibility in Latin America and builds production resilience. Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
• Positive Sentiment: High investor interest and media endorsements (e.g., Jim Cramer) are keeping momentum and retail attention on Moderna amid excitement around its pipeline (including personalized cancer vaccine programs). Jim Cramer on Moderna
• Neutral Sentiment: Moderna says the FDA’s RTF did not raise safety or efficacy concerns and the company does not expect an impact to its 2026 financial guidance; it has requested a Type A meeting and notes mRNA‑1010 is under review in the EU, Canada and Australia — these factors could limit near-term earnings risk but leave U.S. approval uncertain. Moderna Receives Refusal-to-File Letter
• Neutral Sentiment: Upcoming Q4/2025 earnings (scheduled Feb. 13) remain a near-term catalyst — analysts expect pipeline and COVID-vaccine sales updates could influence sentiment regardless of the RTF. Earnings preview
• Negative Sentiment: FDA refused to start review of the flu-vaccine application, issuing an RTF because the pivotal 40,000‑patient trial did not use the “best‑available” U.S. comparator for older adults per the agency — a rare regulatory setback that delays potential U.S. market access and revenue from an important respiratory product. WSJ: FDA refuses to review Moderna’s flu vaccine
• Negative Sentiment: Broader regulatory headwinds under the current U.S. health administration — including tighter vaccine review expectations — raise execution risk for mRNA programs in the U.S., potentially slowing approvals and commercial timelines. Reuters: FDA refuses review
• Negative Sentiment: Recent legal developments (denial of immunity in a high‑stakes vaccine patent case) add litigation risk and potential financial exposure that investors should monitor. Yahoo Finance: Patent immunity denied

Moderna Stock Up 0.1%

Shares of Moderna stock opened at $41.99 on Wednesday. The stock has a market capitalization of $16.41 billion, a price-to-earnings ratio of -5.20 and a beta of 1.32. Moderna has a twelve month low of $22.28 and a twelve month high of $55.20. The company has a 50-day simple moving average of $36.37 and a two-hundred day simple moving average of $29.66.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.